US Bancorp DE Buys 26,467 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU)

US Bancorp DE lifted its stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) by 3,524.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 27,218 shares of the company’s stock after acquiring an additional 26,467 shares during the quarter. US Bancorp DE’s holdings in Caribou Biosciences were worth $43,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in Caribou Biosciences by 6.5% in the 3rd quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock worth $3,980,000 after purchasing an additional 124,782 shares during the period. Barclays PLC boosted its stake in Caribou Biosciences by 122.4% in the 3rd quarter. Barclays PLC now owns 129,839 shares of the company’s stock worth $255,000 after purchasing an additional 71,463 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Caribou Biosciences by 19.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 739,530 shares of the company’s stock worth $1,449,000 after purchasing an additional 118,325 shares during the period. FMR LLC boosted its stake in Caribou Biosciences by 7.4% in the 3rd quarter. FMR LLC now owns 1,581,493 shares of the company’s stock worth $3,100,000 after purchasing an additional 109,606 shares during the period. Finally, Green Alpha Advisors LLC boosted its stake in Caribou Biosciences by 75.4% in the 4th quarter. Green Alpha Advisors LLC now owns 181,054 shares of the company’s stock worth $288,000 after purchasing an additional 77,840 shares during the period. 77.51% of the stock is currently owned by institutional investors.

Caribou Biosciences Stock Performance

NASDAQ CRBU opened at $0.95 on Wednesday. The company has a market capitalization of $88.38 million, a P/E ratio of -0.58 and a beta of 2.34. Caribou Biosciences, Inc. has a one year low of $0.95 and a one year high of $5.77. The stock has a 50 day moving average price of $1.33 and a 200-day moving average price of $1.76.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings data on Monday, March 10th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.01. The company had revenue of $2.08 million during the quarter, compared to analyst estimates of $2.11 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. As a group, equities analysts predict that Caribou Biosciences, Inc. will post -1.64 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on CRBU shares. Citigroup dropped their price target on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, November 26th. Bank of America dropped their price target on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $10.33.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.